BACKGROUND: Despite new opportunities to expand buprenorphine treatment for opioid dependence, use of this treatment modality has been limited. Physicians may question their ability to successfully treat opioid-dependent patients with buprenorphine in a primary care setting. We describe a buprenorphine treatment program and treatment outcomes in an urban community health center. METHODS: We conducted retrospective chart reviews on the first 41 opioid-dependent patients treated with buprenorphine/naloxone. The primary outcome was 90-day retention in treatment. RESULTS: Patients' mean age was 46 years, 70.7% were male, 58.8% Hispanic, 31.7% black, 57.5% unemployed, and 70.0% used heroin prior to treatment. Twenty-nine (70.7%) patients were retained in treatment at day 90. Compared to those not retained, patients retained in treatment were more likely to have used street methadone (0% versus 37.9%) and less likely to have used opioid analgesics (54.6% versus 20.7%) and alcohol (50.0% versus 13.8%) prior to treatment. Of the 25 patients with urine toxicology tests, 24% tested positive for opioids. CONCLUSIONS: Buprenorphine treatment for opioid dependence in an urban community health center resulted in a 90-day retention rate of 70.7%. Type of substance use prior to treatment appeared to be associated with retention. These findings can help guide program development.
BACKGROUND: Despite new opportunities to expand buprenorphine treatment for opioid dependence, use of this treatment modality has been limited. Physicians may question their ability to successfully treat opioid-dependent patients with buprenorphine in a primary care setting. We describe a buprenorphine treatment program and treatment outcomes in an urban community health center. METHODS: We conducted retrospective chart reviews on the first 41 opioid-dependent patients treated with buprenorphine/naloxone. The primary outcome was 90-day retention in treatment. RESULTS:Patients' mean age was 46 years, 70.7% were male, 58.8% Hispanic, 31.7% black, 57.5% unemployed, and 70.0% used heroin prior to treatment. Twenty-nine (70.7%) patients were retained in treatment at day 90. Compared to those not retained, patients retained in treatment were more likely to have used street methadone (0% versus 37.9%) and less likely to have used opioid analgesics (54.6% versus 20.7%) and alcohol (50.0% versus 13.8%) prior to treatment. Of the 25 patients with urine toxicology tests, 24% tested positive for opioids. CONCLUSIONS:Buprenorphine treatment for opioid dependence in an urban community health center resulted in a 90-day retention rate of 70.7%. Type of substance use prior to treatment appeared to be associated with retention. These findings can help guide program development.
Authors: David A Fiellin; Michael V Pantalon; Juliana P Pakes; Patrick G O'Connor; Marek Chawarski; Richard S Schottenfeld Journal: Am J Drug Alcohol Abuse Date: 2002 Impact factor: 3.829
Authors: P G O'Connor; A H Oliveto; J M Shi; E G Triffleman; K M Carroll; T R Kosten; B J Rounsaville; J A Pakes; R S Schottenfeld Journal: Am J Med Date: 1998-08 Impact factor: 4.965
Authors: Chinazo O Cunningham; Hillary V Kunins; Robert J Roose; Rashiah T Elam; Nancy L Sohler Journal: J Gen Intern Med Date: 2007-07-10 Impact factor: 5.128
Authors: E Jennifer Edelman; An T Dinh; Brent A Moore; Richard S Schottenfeld; David A Fiellin; Lynn E Sullivan Journal: J Addict Med Date: 2012-06 Impact factor: 3.702
Authors: Joshua D Lee; Ellie Grossman; Andrea Truncali; John Rotrosen; Andrew Rosenblum; Stephen Magura; Marc N Gourevitch Journal: Subst Abus Date: 2012 Impact factor: 3.716
Authors: Aaron D Fox; Matthew R Anderson; Gary Bartlett; John Valverde; Ross F MacDonald; Lauren I Shapiro; Chinazo O Cunningham Journal: J Health Care Poor Underserved Date: 2014-02
Authors: Sara L Doorley; Cheryl J Ho; Elizabeth Echeverria; Charles Preston; Huy Ngo; Ahmad Kamal; Chinazo O Cunningham Journal: Subst Abus Date: 2016-11-29 Impact factor: 3.716
Authors: Nancy L Sohler; Linda Weiss; James E Egan; Carolina M López; Jamie Favaro; Robert Cordero; Chinazo O Cunningham Journal: J Opioid Manag Date: 2013 Mar-Apr